The market for vasculitis across the globe is expected to propel significantly during the forecast period. The factors driving the vasculitis market are rising incidences of metabolic disorders and circulatory diseases such as peripheral arterial disease (PAD) and high demand for minimally invasive procedures. In addition, the rising healthcare expenditure and R&D vasculitis treatment and supportive reimbursement policies are estimated to impact the market positively during the forecast period. Due to the advancement in the treatment, vasculitis can be controlled and now it can be completely cured. However, the side effect associated to treatment such as weight gain, diabetes and bone thinning are now serious issue. Many researches are going on to identify the main cause of vasculitis and various research institutes are providing funds for these researches. For instance, University of Cambridge have received funding from Arthritis Research UK to investigate cause of disease called ANCA-associated vasculitis.